Jonasch, E., Hasanov, E., Campbell, M. T., Tannir, N. M., Tidwell, R. S., Hwang, H., Wood, L. M., Syed, M., Solley, T., Fares, S., Brooks, E., Cazares, J., Allman, K., Venkatesan, A. M., Surasi, D. S. (2026). Phase 1B/2 study of combination
                    <sup>177</sup>
                    Lu girentuximab plus cabozantinib and nivolumab in treatment-naïve patients with advanced clear cell RCC.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.tps582